CR20200216A - Polimorfos y formas sòlidas de un compuesto de pirimidinilamino-pirazol y mèdtodos de producciòn - Google Patents
Polimorfos y formas sòlidas de un compuesto de pirimidinilamino-pirazol y mèdtodos de producciònInfo
- Publication number
- CR20200216A CR20200216A CR20200216A CR20200216A CR20200216A CR 20200216 A CR20200216 A CR 20200216A CR 20200216 A CR20200216 A CR 20200216A CR 20200216 A CR20200216 A CR 20200216A CR 20200216 A CR20200216 A CR 20200216A
- Authority
- CR
- Costa Rica
- Prior art keywords
- pyrimidinylamine
- polymorphes
- pirazole
- compound
- production methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
<p>La presente descripción hace referencia a formas amorfas y polimórficas cristalinas de 2-metil2-(3-metil-4-(4-(metilamino)-5-(trifluorometil)pirimidin-2-ilamino)-1H-pirazol-1-il)propanonitrilo o solvatos, tautómeros y cocristales o sales farmacéuticamente aceptables de este, así como a procesos para su elaboración.</p>
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762589276P | 2017-11-21 | 2017-11-21 | |
| PCT/US2018/062102 WO2019104086A1 (en) | 2017-11-21 | 2018-11-20 | Polymorphs and solid forms of a pyrimidinylamino-pyrazole compound, and methods of production |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20200216A true CR20200216A (es) | 2021-03-19 |
Family
ID=66631734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20200216A CR20200216A (es) | 2017-11-21 | 2018-11-20 | Polimorfos y formas sòlidas de un compuesto de pirimidinilamino-pirazol y mèdtodos de producciòn |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US10370361B2 (es) |
| EP (1) | EP3717473B1 (es) |
| JP (1) | JP7303821B2 (es) |
| KR (1) | KR102878525B1 (es) |
| CN (1) | CN111819174A (es) |
| AR (1) | AR113893A1 (es) |
| AU (1) | AU2018372180B2 (es) |
| CA (1) | CA3083022A1 (es) |
| CL (1) | CL2020001346A1 (es) |
| CO (1) | CO2020006206A2 (es) |
| CR (1) | CR20200216A (es) |
| EA (1) | EA202091279A1 (es) |
| ES (1) | ES2975319T3 (es) |
| IL (1) | IL274824B1 (es) |
| JO (1) | JOP20200128A1 (es) |
| MA (1) | MA51222A (es) |
| MX (1) | MX2020005332A (es) |
| MY (1) | MY209751A (es) |
| PE (1) | PE20210157A1 (es) |
| PH (1) | PH12020550700A1 (es) |
| SG (1) | SG11202004733WA (es) |
| TW (1) | TWI823878B (es) |
| UA (1) | UA126414C2 (es) |
| WO (1) | WO2019104086A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR113893A1 (es) | 2017-11-21 | 2020-06-24 | Denali Therapeutics Inc | Polimorfos y formas sólidas de un compuesto de pirimidinilamino-pirazol y métodos de producción |
| CA3086182A1 (en) | 2017-12-20 | 2019-06-27 | Denali Therapeutics Inc. | Process for the preparation of pyrimidinyl-4-aminopyrazole compounds |
| CA3195193A1 (en) | 2020-10-29 | 2022-05-05 | Peter H. Fuller | N-linked isoquinoline amides as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof |
| WO2023174946A1 (en) | 2022-03-15 | 2023-09-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Early and non-invasive method for assessing a subject's risk of having parkinson's disease |
| US12272712B2 (en) | 2022-05-14 | 2025-04-08 | Xintec Inc. | Chip package and method for forming a chip package having first and second stack of dummy metal layers surround the sensing region |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR084691A1 (es) | 2010-05-21 | 2013-06-05 | Incyte Corp | Formulacion de uso topico para un inhibidor de jak y metodo para tratar trastorno de la piel |
| US8354420B2 (en) | 2010-06-04 | 2013-01-15 | Genentech, Inc. | Aminopyrimidine derivatives as LRRK2 inhibitors |
| GB201015949D0 (en) | 2010-09-22 | 2010-11-03 | Medical Res Council Technology | Compounds |
| SI2638031T1 (en) * | 2010-11-10 | 2018-02-28 | Genentech, Inc. | Pyrazole aminopyrimidine derivatives as LRRK2 modulators |
| AR089182A1 (es) | 2011-11-29 | 2014-08-06 | Hoffmann La Roche | Derivados de aminopirimidina como moduladores de lrrk2 |
| CN103958498B (zh) | 2011-11-29 | 2016-09-07 | 霍夫曼-拉罗奇有限公司 | 作为lrrk2调节剂的氨基嘧啶衍生物 |
| CA2852609C (en) | 2011-11-29 | 2020-03-10 | F. Hoffmann-La Roche Ag | Aminopyrimidine derivatives as lrrk2 modulators |
| LT2785711T (lt) | 2011-11-29 | 2016-10-25 | F.Hoffmann-La Roche Ag | 2-(fenil arba pirid-3-il)aminopirimidino dariniai kaip kinazės lrrk2 moduliatoriai skirti parkinsono ligos gydymui |
| BR112014027117B1 (pt) | 2012-05-03 | 2022-09-06 | Genentech, Inc | Derivados de pirazol aminopirimidina como moduladores de lrrk2, seus usos, e composição |
| WO2013164321A1 (en) * | 2012-05-03 | 2013-11-07 | F. Hoffmann-La Roche Ag | Pyrazole aminopyrimidine derivatives as lrrk2 modulators |
| IL299415B2 (en) * | 2016-06-16 | 2025-09-01 | Denali Therapeutics Inc | Pyrimidine-2-ylamino-1H-pyrazoles as LRRK2 inhibitors for use in the treatment of neurodegenerative disorders |
| AR113893A1 (es) | 2017-11-21 | 2020-06-24 | Denali Therapeutics Inc | Polimorfos y formas sólidas de un compuesto de pirimidinilamino-pirazol y métodos de producción |
-
2018
- 2018-11-20 AR ARP180103389A patent/AR113893A1/es unknown
- 2018-11-20 IL IL274824A patent/IL274824B1/en unknown
- 2018-11-20 PE PE2020000558A patent/PE20210157A1/es unknown
- 2018-11-20 ES ES18881859T patent/ES2975319T3/es active Active
- 2018-11-20 CR CR20200216A patent/CR20200216A/es unknown
- 2018-11-20 MX MX2020005332A patent/MX2020005332A/es unknown
- 2018-11-20 WO PCT/US2018/062102 patent/WO2019104086A1/en not_active Ceased
- 2018-11-20 MY MYPI2020002460A patent/MY209751A/en unknown
- 2018-11-20 SG SG11202004733WA patent/SG11202004733WA/en unknown
- 2018-11-20 US US16/197,037 patent/US10370361B2/en active Active
- 2018-11-20 CA CA3083022A patent/CA3083022A1/en active Pending
- 2018-11-20 KR KR1020207017598A patent/KR102878525B1/ko active Active
- 2018-11-20 JO JOP/2020/0128A patent/JOP20200128A1/ar unknown
- 2018-11-20 MA MA051222A patent/MA51222A/fr unknown
- 2018-11-20 AU AU2018372180A patent/AU2018372180B2/en active Active
- 2018-11-20 UA UAA202003681A patent/UA126414C2/uk unknown
- 2018-11-20 JP JP2020545076A patent/JP7303821B2/ja active Active
- 2018-11-20 TW TW107141257A patent/TWI823878B/zh active
- 2018-11-20 EA EA202091279A patent/EA202091279A1/ru unknown
- 2018-11-20 EP EP18881859.5A patent/EP3717473B1/en active Active
- 2018-11-20 PH PH1/2020/550700A patent/PH12020550700A1/en unknown
- 2018-11-20 CN CN201880081321.5A patent/CN111819174A/zh active Pending
-
2019
- 2019-06-20 US US16/447,713 patent/US10851088B2/en active Active
-
2020
- 2020-05-21 CO CONC2020/0006206A patent/CO2020006206A2/es unknown
- 2020-05-21 CL CL2020001346A patent/CL2020001346A1/es unknown
- 2020-11-27 US US17/105,870 patent/US11427571B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20250289A1 (ar) | صور بلورية جديدة | |
| PH12020550700A1 (en) | Polymorphs and solid forms of a pyrimidinylamino-pyrazole compound, and methods of production | |
| EA202091115A1 (ru) | Производные хиназолина, применяемые для лечения вич | |
| EA201791305A1 (ru) | Конденсированные пиримидины для лечения вич | |
| EA201791304A1 (ru) | Производные изохинолина для лечения вич | |
| IL279101A (en) | Salts of spiafatrin are accepted in pharmacies | |
| CL2017001617A1 (es) | Formas sólidas de un inhibidor ask1 referencia cruzada a aplicaciones relacionadas | |
| JOP20220305A1 (ar) | ستيرويد 19- نور c3، 3- به استبدال ثنائي لـ c21-n بيرازوليل بلوري | |
| MX391812B (es) | Agonista fxr derivado de esteroides. | |
| WO2016011390A8 (en) | Irak4 inhibiting agents | |
| CL2019003857A1 (es) | Composiciones y métodos de uso de 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida solicitudes relacionadas. | |
| WO2015132799A3 (en) | Heterocyclic compounds | |
| PH12019501639A1 (en) | Jaki selective inhibitors | |
| MX392634B (es) | Sal de un compuesto derivado de aminopiridina, una forma cristalina de esta y un proceso para prepararlo | |
| WO2016044641A3 (en) | Carm1 inhibitors and uses thereof | |
| JOP20190233A1 (ar) | نظائر بنزوازيبين بوصفها عوامل مثبطة لتيروزين كيناز بروتون | |
| JOP20200256A1 (ar) | طريقة لتحضير 1، 2، 4-تريازولون يحمل ثلاثة بدائل في المواقع 2، 4، 5 | |
| UY38233A (es) | Agentes inhibidores para la tirosina cinasa de bruton | |
| EP4275707A3 (en) | Formulations of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide | |
| PH12020551465A1 (en) | Solid forms of substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds | |
| IL276430A (en) | A pharmaceutical compound, its cures, its formulations, and methods for its preparation and use | |
| WO2015111085A8 (en) | Processes for the preparation of eltrombopag and pharmaceutically acceptable salts, solvates and intermediates thereof | |
| ES3065261T3 (en) | Crystalline form of a multi-tyrosine kinase inhibitor, method of preparation, and use thereof | |
| MX2018014759A (es) | Sal farmaceuticamente aceptable como inhibidor del canal de potasio medular externo renal. | |
| CL2017002180A1 (es) | Formas cristalinas de un compuesto de pirrolopiridina |